1272 related articles for article (PubMed ID: 19457126)
21. Dieldrin induces ubiquitin-proteasome dysfunction in alpha-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death.
Sun F; Anantharam V; Latchoumycandane C; Kanthasamy A; Kanthasamy AG
J Pharmacol Exp Ther; 2005 Oct; 315(1):69-79. PubMed ID: 15987830
[TBL] [Abstract][Full Text] [Related]
22. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
[TBL] [Abstract][Full Text] [Related]
23. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
24. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
[TBL] [Abstract][Full Text] [Related]
26. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
27. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
[TBL] [Abstract][Full Text] [Related]
28. Pale body-like inclusion formation and neurodegeneration following depletion of 26S proteasomes in mouse brain neurones are independent of α-synuclein.
Paine SM; Anderson G; Bedford K; Lawler K; Mayer RJ; Lowe J; Bedford L
PLoS One; 2013; 8(1):e54711. PubMed ID: 23382946
[TBL] [Abstract][Full Text] [Related]
29. Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity.
Fornai F; Lazzeri G; Bandettini Di Poggio A; Soldani P; De Blasi A; Nicoletti F; Ruggieri S; Paparelli A
Ann N Y Acad Sci; 2006 Aug; 1074():84-9. PubMed ID: 17105905
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
31. Ubiquitin-proteasome system and Parkinson's diseases.
Betarbet R; Sherer TB; Greenamyre JT
Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
[TBL] [Abstract][Full Text] [Related]
32. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
33. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
34. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
35. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
36. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease.
McNaught KS; Olanow CW
Neurobiol Aging; 2006 Apr; 27(4):530-45. PubMed ID: 16207501
[TBL] [Abstract][Full Text] [Related]
37. Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis.
Cheng YF; Zhu GQ; Wang M; Cheng H; Zhou A; Wang N; Fang N; Wang XC; Xiao XQ; Chen ZW; Li QL
Neurosci Res; 2009 Jan; 63(1):52-8. PubMed ID: 19022306
[TBL] [Abstract][Full Text] [Related]
38. Embryonic stem cell-derived neuron models of Parkinson's disease exhibit delayed neuronal death.
Yamashita H; Nakamura T; Takahashi T; Nagano Y; Hiji M; Hirabayashi T; Amano T; Yagi T; Sakai N; Kohriyama T; Matsumoto M
J Neurochem; 2006 Jul; 98(1):45-56. PubMed ID: 16805795
[TBL] [Abstract][Full Text] [Related]
39. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.
Ross CA; Pickart CM
Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047
[TBL] [Abstract][Full Text] [Related]
40. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
